{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-126734","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.134631+00:00","generated_at":"2026-05-30T00:30:11.247485+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Iterum Therapeutics Q3 net loss $6.1M; FDA approved ORLYNVAH in October 2024","bullets":["Cash, cash equivalents and short-term investments totaled $14.5M at Sept. 30, 2024.","FDA approved ORLYNVAH for uUTI on Oct. 25, 2024; 10 years of GAIN Act exclusivity.","Net loss Q3 2024 was $6.1M vs $3.9M in Q3 2023; non-GAAP net loss $4.8M vs $15.7M.","R&D expenses fell to $3.1M from $14.9M due to completion of REASSURE trial enrollment.","Company seeking strategic partners for ORLYNVAH; cash expected to fund into 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-126734","json":"https://secwatch.observer/filing/0000950170-24-126734.json","markdown":"https://secwatch.observer/filing/0000950170-24-126734.md","text":"https://secwatch.observer/filing/0000950170-24-126734.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024126734/0000950170-24-126734-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024126734/itrm-20241114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:30:11.247485+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}